Spots Global Cancer Trial Database for PR104 and G-CSF in Treating Patients With Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: PR104 and G-CSF in Treating Patients With Solid Tumors

Official Title: A Phase I, Multi-Center, Open-Label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR104 Given With Prophylactic G-CSF in Subjects With Solid Tumors

Study ID: NCT00616213

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

filgrastim

PR104

F-18-fluoromisonidazole

Study Description

Brief Summary: RATIONALE: Drugs used in chemotherapy, such as PR-104, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as G-CSF, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. Giving PR-104 together with G-CSF may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of PR-104 when given together with G-CSF in treating patients with solid tumors.

Detailed Description: OBJECTIVES: Primary * Determine the maximum tolerated dose of PR-104 in combination with filgrastim (G-CSF) in patients with solid tumors. Secondary * Characterize the safety of this regimen in these patients. * Evaluate the pharmacokinetics of PR-104 and its alcohol metabolite. * Evaluate the rate of hypoxia in various solid tumors using F-MISO PET (18F-fluoromisonidazole positron emission tomography) imaging. * Assess for antitumor toxicity in these patients. * Collect plasma samples for the assessment of potential biomarkers of tumor hypoxia. OUTLINE: This is a multicenter, dose-escalation study of PR-104. Patients receive PR-104 IV over 1 hour on day 1 and filgrastim (G-CSF) on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo 18F-fluoromisonidazole PET scans at baseline and prior to course 3 to assess tumor hypoxia. Patients undergo blood sample collection periodically during course 1. Samples are analyzed for the pharmacokinetics of PR-104 and for identification of biomarkers for tumor hypoxia. After completion of study treatment, patients are followed at 30 days.